Dyne Therapeutics, Inc. $DYN Shares Bought by Aberdeen Group plc

Key Points

• Aberdeen Group plc significantly increased its stake in Dyne Therapeutics by 1,119.2%, acquiring 288,783 additional shares for a total ownership of approximately 0.28% valued at $3.29 million.
• Several analysts adjusted their price targets for Dyne Therapeutics, with Oppenheimer lowering its target from $34 to $13, while two analysts rated the stock as a Strong Buy.
• Dyne Therapeutics reported a quarterly loss of ($0.97) earnings per share, exceeding the consensus estimate of ($0.99), indicating some operational resilience amidst potential challenges.

Aberdeen Group plc raised its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 1,119.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 314,586 shares of the company's stock after buying an additional 288,783 shares during the quarter. Aberdeen Group plc owned approximately 0.28% of Dyne Therapeutics worth $3,291,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. purchased a new position in shares of Dyne Therapeutics during the 1st quarter worth $179,000. E Fund Management Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 16.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock worth $144,000 after purchasing an additional 1,923 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in shares of Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock worth $32,000 after purchasing an additional 2,446 shares during the period. Nuveen LLC purchased a new position in shares of Dyne Therapeutics during the 1st quarter worth $2,335,000. Finally, Invesco Ltd. grew its holdings in shares of Dyne Therapeutics by 64.4% during the 1st quarter. Invesco Ltd. now owns 66,293 shares of the company's stock worth $693,000 after purchasing an additional 25,970 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Trading Up 2.9%

DYN traded up $0.36 during mid-day trading on Friday, hitting $12.58. 2,298,424 shares of the stock were exchanged, compared to its average volume of 3,077,638. The firm's fifty day moving average is $10.23 and its two-hundred day moving average is $11.20. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $46.81. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.79 billion, a PE ratio of -3.26 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.02. Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on DYN. HC Wainwright lowered their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Guggenheim reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Raymond James Financial reiterated an "outperform" rating and set a $31.00 price target (down from $37.00) on shares of Dyne Therapeutics in a report on Tuesday, July 29th. JPMorgan Chase & Co. decreased their target price on Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Finally, Stifel Nicolaus decreased their target price on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of "Buy" and a consensus price target of $33.80.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox purchased 100,000 shares of Dyne Therapeutics stock in a transaction on Monday, July 14th. The shares were bought at an average price of $9.11 per share, with a total value of $911,000.00. Following the transaction, the chief executive officer directly owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.14% of the stock is owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.